As Novo Nordisk A/S and Eli Lilly and Co. go head-to-head in the U.S. and Chinese glucagon-like peptide-1 receptor agonists ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 607.25% and ...

Discover Citi's bullish outlook on Eli Lilly with a $1,060 target. Is now the time to invest? Find key insights and price ...

A growing number of people with type 1 diabetes are becoming overweight or obese, in part because insulin can cause weight ...

In a report released today, Peter Verdult from Citi initiated coverage with a Buy rating on Eli Lilly & Co (LLY – Research Report) ...

People taking the experimental drug amycretin were found to lose almost twice as much weight over a 12-week period as the ...

Gasiorek reported employment with Novo Nordisk. The FAERS analysis was funded by Università degli Studi di Bari Aldo Moro within the CRUI-CARE Agreement. Caruso reported relationships with Eli Lilly ...

Chinese pharmaceutical and biotech companies are leading development of glucagon-like peptide-1 receptor agonists as Novo ...

Aude Bandini has received funding from the Arts and Humanities Research Council. Jean-Philippe Drouin-Chartier has received research funding from Dairy Farmers of Canada and the Weston Family ...

Eli Lilly & Co.’s blockbuster obesity shot Zepbound helped people with type 1 diabetes lose more than a fifth of their body ...

Weight loss drugs are likely to stay in demand for a long time judging by the obesity trend as shown by latest CDC data ...

Pharmaceutical companies must prioritize efforts to reach patients in underserved parts of the world with medicines such as insulin for diabetics and, crucially, measure the effectiveness of these ...